Cellectar Biosciences (CLRB) Price & Analysis

Compare

1,424 Followers

CLRB Stock Chart & Stats

Day’s Range― - ―

52-Week Range$4.23 - $68.70

Previous CloseN/A

Volume1.30M

Average Volume (3M)136.62K

Market Cap

$13.85M

Enterprise Value$2.75M

Total Cash (Recent Filing)$11.04M

Total Debt (Recent Filing)$453.51K

Price to Earnings (P/E)―

Beta1.21

Next Earnings

Oct 30, 2025

EPS Estimate

-2.53

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-3.39

Shares Outstanding3,192,040

10 Day Avg. Volume167,327

30 Day Avg. Volume136,618

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.20

Enterprise Value/Revenue8.91

Enterprise Value/Gross Profit92.89

Enterprise Value/Ebitda-0.07

Forecast

1Y Price Target

$15.20

Price Target Upside250.23% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Regulatory ApprovalCellectar recently held a meeting with the FDA, which confirmed a clear path to accelerated approval for Iopofosine-131 in Waldenstrom’s macroglobulinemia.

Strategic PartnershipsCellectar remains in active discussions with potential partners to out-license Iopofosine-131 in Waldenstrom’s macroglobulinemia.

Bears Say

Financial PerformanceCellectar reported 2Q25 results with a net loss of ($5.4M) and ended the period with $11.0M in cash.

Strategic UncertaintyThe strategic pivot introduces material uncertainty regarding the future development of Cellectar's radiopharma programs.

Cellectar Biosciences News

Cellectar Biosciences target adjusted to $18 from $3 at Roth Capital

Roth Capital adjusted the firm’s price target on Cellectar Biosciences (CLRB) to $18 from $3 and keeps a...

4d ago

CLRB

Cellectar Biosciences reports Q2 EPS ($3.39), consensus ($3.70)

“Throughout the first half of 2025 we made meaningful progress advancing our pipeline of targeted radiopharmaceuticals and are...

4d ago

CLRB

Cellectar Biosciences Reports Q2 2025 Financial Results

Cellectar Biosciences Inc ( ($CLRB) ) has released its Q2 earnings. Here is a breakdown of the information...

3d ago

CLRB

CLRB Upcoming Earnings Report: What to Expect?

Cellectar Biosciences Inc (CLRB) is scheduled to report 2nd quarter earnings on 08/14/2025, before the market opens. Regarding...

6d ago

CLRB

Cellectar prices 865,000 units at $5.00 in underwritten public offering

Cellectar Biosciences (CLRB) announced the pricing of an underwritten public offering for gross proceeds of approximately $6M prior...

2M ago

CLRB

Cellectar Biosciences Plans Phase 1 Cancer Studies

The latest update is out from Cellectar Biosciences ( ($CLRB) ). Cellectar Biosciences announced updates on their investigational...

2M ago

CLRB

Cellectar Biosciences files to sell 755,667 Class A Units

Ladenburg Thalmann is acting as manager. Published first on TheFly – the ultimate source for real-time, market-moving breaking...

2M ago

CLRB

Cellectar Biosciences, Nusano enter into multi-isotope supply agreement

Cellectar Biosciences (CLRB) announced the signing of a multi-year supply agreement in which Nusano will provide Cellectar with...

2M ago

CLRB

Cellectar submits a protocol with U.S. FDA for Phase 1b Dose Finding study

Cellectar Biosciences (CLRB) announced that the company has submitted a protocol with the U.S. Food and Drug Administration,...

2M ago

CLRB

Cellectar Biosciences trading halted, news pending

19:50 EDT Cellectar Biosciences (CLRB) trading halted, news pending Published first on TheFly – the ultimate source for...

2M ago

CLRB

Upcoming Stock Splits This Week (June 23 to June 27) – Stay Invested

These are the upcoming stock splits for the week of June 23 to June 27, based on TipRanks’ Stock...

2M ago

SLE

CLRB

Cellectar Biosciences Announces Reverse Stock Split

Cellectar Biosciences ( ($CLRB) ) has issued an update. On June 18, 2025, Cellectar Biosciences announced a one-for-thirty...

2M ago

CLRB

Cellectar Biosciences announces 1-for-30 reverse stock split

Cellectar Biosciences (CLRB) announced a one-for-thirty reverse stock split of the company’s common stock, par value $0.00001, which...

2M ago

CLRB

Cellectar Biosciences Approves Reverse Stock Split Proposal

Cellectar Biosciences ( ($CLRB) ) has issued an update. Cellectar Biosciences, Inc. held its 2025 Annual Meeting of...

2M ago

CLRB

CLRB FAQ

What was Cellectar Biosciences Inc’s price range in the past 12 months?

Cellectar Biosciences Inc lowest stock price was $4.22 and its highest was $68.70 in the past 12 months.

What is Cellectar Biosciences Inc’s market cap?

Cellectar Biosciences Inc’s market cap is $13.85M.

When is Cellectar Biosciences Inc’s upcoming earnings report date?

Cellectar Biosciences Inc’s upcoming earnings report date is Oct 30, 2025 which is in 73 days.

How were Cellectar Biosciences Inc’s earnings last quarter?

Cellectar Biosciences Inc released its earnings results on Aug 14, 2025. The company reported -$3.39 earnings per share for the quarter, beating the consensus estimate of -$3.719 by $0.329.

Is Cellectar Biosciences Inc overvalued?

According to Wall Street analysts Cellectar Biosciences Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cellectar Biosciences Inc pay dividends?

Cellectar Biosciences Inc does not currently pay dividends.

What is Cellectar Biosciences Inc’s EPS estimate?

Cellectar Biosciences Inc’s EPS estimate is -2.53.

How many shares outstanding does Cellectar Biosciences Inc have?

Cellectar Biosciences Inc has 3,192,040 shares outstanding.

What happened to Cellectar Biosciences Inc’s price movement after its last earnings report?

Cellectar Biosciences Inc reported an EPS of -$3.39 in its last earnings report, beating expectations of -$3.719. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Cellectar Biosciences Inc?

Currently, no hedge funds are holding shares in CLRB

Cellectar Biosciences Stock Smart Score

Underperform

Fundamentals

Return on Equity

-273.88%

Trailing 12-Months

Asset Growth

-53.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Cellectar Biosciences Inc

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

Cellectar Biosciences (CLRB) Earnings & Revenues

Historic Earnings Reports

CLRB Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in clinical trials and a substantial reduction in net loss, suggesting strong operational improvements. However, financial constraints and reliance on strategic partnerships indicate challenges ahead.View all CLRB earnings summaries

CLRB Stock 12 Month Forecast

Average Price Target

$15.20

▲(250.23% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","34":"$34","65":"$65","96":"$96","127":"$127"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$15.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,34,65,96,127],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Dec<br/>2024","9":"Apr<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.72,5.741538461538461,6.763076923076923,7.784615384615385,8.806153846153848,9.82769230769231,10.84923076923077,11.87076923076923,12.892307692307693,13.913846153846155,14.935384615384617,15.95692307692308,16.97846153846154,{"y":18,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.72,5.526153846153846,6.332307692307692,7.138461538461538,7.944615384615385,8.75076923076923,9.556923076923077,10.363076923076925,11.169230769230769,11.975384615384616,12.78153846153846,13.587692307692308,14.393846153846155,{"y":15.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.72,5.310769230769231,5.901538461538461,6.492307692307692,7.0830769230769235,7.673846153846154,8.264615384615386,8.855384615384615,9.446153846153846,10.036923076923078,10.627692307692307,11.21846153846154,11.80923076923077,{"y":12.4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":126,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.8,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":76.5,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.8,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.4,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":60.9,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.6,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.97,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.68,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 10</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":8.76,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.93,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.86,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.72,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >